iBio (IBIO) Cash from Financing Activities (2012 - 2026)

iBio (IBIO) has reported Cash from Financing Activities for 15 consecutive years, with $28.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 2548.54% year-over-year to $28.2 million; the TTM figure through Mar 2026 stood at $91.8 million (up 568.25% YoY), while the FY2025 annual figure was $8.9 million, down 63.55% from the prior year.
• Cash from Financing Activities improved to $28.2 million in Q1 2026 per IBIO's latest filing, from $8.8 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $46.7 million in Q3 2025 and bottomed at -$3.0 million in Q4 2022.
• Historically, Cash from Financing Activities has averaged $7.0 million across 5 years, with a median of $2.5 million in 2023.
• Annual changes were most pronounced in 2024 — Cash from Financing Activities plunged 106.55% — and 2025, when it surged 28930.25%.
• iBio's Cash from Financing Activities stood at -$3.0 million in 2022, then jumped by 231.57% to $4.0 million in 2023, then tumbled by 103.8% to -$152000.0 in 2024, then jumped by 5879.61% to $8.8 million in 2025, then jumped by 220.48% to $28.2 million in 2026.
• Business Quant data shows IBIO's Cash from Financing Activities at $28.2 million in Q1 2026, $8.8 million in Q4 2025, and $46.7 million in Q3 2025.